Remove Antibody Remove Clinical Supply Remove Development Remove Reagent
article thumbnail

IN FOCUS: Syngene International

Pharmaceutical Technology

The company has been ranked in the Business Expansion and Research and Development categories in the Pharmaceutical Technology Excellence Rankings. The 10-year agreement is for manufacturing the drug substance for Librela® (bedinvetmab), a first-in-class monoclonal antibody used for treating osteoarthritis in dogs. until 2026.